Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Эмпаглифлозин, сердечно-сосудистые исходы и смертность при сахарном диабете 2-го типа
2015-09-17
SCID: 54.1/z8cnnsg8
Discuss with AI
Cardiovascular outcomesEmpagliflozinMortalitySodium-glucose cotransporter 2 inhibitorsType 2 diabetes
Figures from the paper
Abstract (AI)
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina. RESULTS: A total of 7020 patients were treated (median observation time, 3.1 years). The primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There were no significant between-group differences in the rates of myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization for heart failure (2.7% and 4.1%, respectively; 35% relative risk reduction), and death from any cause (5.7% and 8.3%, respectively; 32% relative risk reduction). There was no significant between-group difference in the key secondary outcome (P=0.08 for superiority). Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events. CONCLUSIONS: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).
Key Findings
1
All-cause mortality was significantly lower with empagliflozin than placebo (5.7% vs. 8.3%; 32% relative risk reduction).
2
Empagliflozin increased genital infections but was not associated with an increase in other adverse events reported in the abstract.
3
Empagliflozin significantly reduced cardiovascular death (3.7% vs. 5.9%; 38% relative risk reduction) and hospitalization for heart failure (2.7% vs. 4.1%; 35% relative risk reduction).
4
In 7020 high-cardiovascular-risk patients with type 2 diabetes, empagliflozin reduced the primary cardiovascular composite outcome versus placebo (10.5% vs. 12.1%; hazard ratio, 0.86).
5
Myocardial infarction and stroke rates did not differ significantly between treatment groups, and the key secondary composite outcome was not significantly reduced.
Research Object
Use of empagliflozin added to standard care in patients with type 2 diabetes at high cardiovascular risk
Research Subject
Cardiovascular morbidity, cardiovascular and all-cause mortality, and related clinical outcomes
Publication Details
Publication Date
2015-09-17
Journal
Publisher
ISSN
Cited by
12605
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by20
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2021
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2016
2018 ESC/ESH Guidelines for the management of arterial hypertension2018
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes2016
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes2016
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2016
2023 ESC Guidelines for the management of acute coronary syndromes2023
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2020
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2018
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension2023
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association2021
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2022
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2022
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)2016
Clinical Update: Cardiovascular Disease in Diabetes Mellitus2016
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function2020